Great talk so far. Thanks for the reminder.

Great talk so far. Thanks for the reminder.

Interesting that he showed the data missing from the IJID pre-print (right panel of Figure 2 A), with control Covid patients (no LL treatment). Hard to see though.

Other tidbits:

Maraviroc slightly faster receptor occupancy filling than leronlimab

Shift from M2 to M1 macrophage polarization with CCR5a tx

Key in cancer is CCR5a dosing so that block TReg migration to TME (blocking the blockers), but allow the beneficial T-memory cells and CD8 T-cells, which go and kill the cancer cells.

Nice to see details about LongHaulers Index - as ranking of 14 cytokine panel and other biomarkers vs. healthy controls. 100% perfect classification so far.

Trying to develop similar biomarker panel to predict who will develop severe Covid.

10-30% of Covid infections lead to chronic Covid symptoms (i.e. Long Haulers)

Selling his cytokine panel monitoring, but agree it is useful potentially to look at all these things to decide which treatment to give when.

I wonder if CYDY has any interest of collaborating and using the LHI for LH trial.